SELLAS (SLS) stock jumps 12% as investors watch the Phase 3 REGAL AML trial, short interest, and squeeze risk.
Zacks Investment Research on MSN
Gilead Sciences (GILD) sees a more significant dip than broader market: Some facts to know
In the latest close session, Gilead Sciences (GILD) was down 1.48% at $134.28. This change lagged the S&P 500's daily loss of 1.01%. Meanwhile, the Dow lost 0.77%, and the Nasdaq, a tech-heavy index, ...
Cassava Sciences (SAVA) said it will change its name to Filana Therapeutics, reflecting its focus on developing drugs that target the filamin A protein to treat central nervous system disorders. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results